Immune drug atezolizumab tested before bladder cancer surgery

NCT ID NCT04624399

Recruiting now Disease control Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether the drug atezolizumab can shrink tumors in people with urothelial cancer before they have surgery. Participants receive two doses of atezolizumab, then undergo standard surgery to remove the tumor. Researchers will compare tissue and blood samples to see how well the drug works and if it is safe. The study is recruiting 58 patients in the UK, France, and Spain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab (a drug that helps the immune system attack cancer cells)
What this could lead to: If it works, this could show that giving atezolizumab before surgery helps shrink tumors and improve outcomes for people with urothelial cancer.
What could go wrong: This is a small, early-phase trial (58 participants) and may not prove the drug works for everyone. Side effects from atezolizumab or surgery are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE UROTHELIUM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pure squamous carcinoma of the urothelial tract renal pelvis/ureter urothelial carcinoma reproductive system cancer Urogenital Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UROGENITAL CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Barts and London Hospital NHS Trust
RECRUITING

London, United Kingdom

Contact

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.